<DOC>
	<DOCNO>NCT00373412</DOCNO>
	<brief_summary>Objectives trial : Evaluate kinetics magnitude CMV-specific immune response post-Towne challenge ( 3000 pfu ) healthy CMV-seronegative volunteer receive VCL CT02 administer ( 1 mg weekly x 3 ) 3 month previously compare randomize control receive VCL CT02 measure : 1. antibody titer gB ; 2 . T-cell IFN-g ELISPOT ; 3 . T-cell proliferation assay IE1 , pp65 , and/or gB ; 4. cytokine phenotypic flow cytometry response pp65 , IE1 , and/or gB . Evaluate safety safety Towne challenge healthy CMV-seronegative adult subject previously immunize trivalent pDNA CMV vaccine ( VCL-CT02 ) administer intramuscularly . Our hypothesis immune response Towne vaccine 3000 pfu challenge VLC-CT02 priming great Towne vaccination alone .</brief_summary>
	<brief_title>Trial pDNA CMV Vaccine ( VCL-CT02 ) Followed Towne CMV Vaccine ( Towne ) Challenge</brief_title>
	<detailed_description>This Phase 1 , single-center , randomize , open-label trial live , attenuate Towne CMV vaccine administer `` challenge '' healthy , CMV-seronegative , adult subject previously receive CMV immunotherapeutic trivalent pDNA-based vaccine , VCL-CT02 , give intramuscular route Days 1 , 7 14 receive VCL-CT02 . Up 12 healthy , CMV-seronegative subject enrol . If subject consent meet eligibility criterion , subject randomize VCL CT02 ( N=6 ) control ( N=6 ) group . VCL CT02-assigned subject receive VCL CT02 ( 1 mg weekly x 3 ) Day 77 receive Towne vacine ( 3000 pfu subcutaneously ) . Control-assigned subject receive Towne alone . Safety monitor antibody CMV gB T-cell response CMV antigen measure specified interval 252 day post Towne challenge .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 45 year age Normal lab value study entry Good general health Negative CMV IgG antibody test CMV seropositive Recent vaccination ( ) Immunodeficiency Vaccination investigational CMV vaccine ( ) Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>vaccine</keyword>
	<keyword>T cell</keyword>
	<keyword>antibody</keyword>
</DOC>